Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07YPW
|
|||
| Former ID |
DIB014334
|
|||
| Drug Name |
Shigamabs
|
|||
| Synonyms |
C-Stx1; C-Stx2; Ca-Stx1; Ca-Stx2; Anti-Shiga toxin monoclonal antibodies, Thallion; Anti-Shiga toxin monoclonals, Sunol;Monoclonal antibodies (HUS), Sunol; Monoclonal antibodies (HUS), Thallion
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Phase 3 | [1] | |
| Haemolytic uraemic syndrome [ICD-11: 3A21.2; ICD-10: D59.3] | Phase 2 | [2] | ||
| Company |
Bellus Health
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Shiga toxin 2 subunit B (Bact stxII) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of BELLUS Health Inc. | |||
| REF 2 | Company report (Bellus Health) | |||
| REF 3 | Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.